Ascendia

  MARKET NEWS

atai Life Sciences Announces $50 Million Private Placement Financing
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan)
Aptamer Group Identifies Novel Target to Enable Cell-Specific Gene Therapy for Liver Fibrosis
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Simtra BioPharma Solutions Expands Halle/Westfalen, Germany Facility with the Addition of a New Production Building

  EXPERT CONTENT & RESOURCES

Exploring New Potential Through 505(b)(2)

Exploring New Potential Through 505(b)(2)

When filing for a drug product approval via the 505(b)(2) regulatory pathway rather than a traditional development pathway, companies are afforded several advantages.

Ionizable Lipids in LNPs: A Selection Guide

Ionizable Lipids in LNPs: A Selection Guide

Finding the right ionizable lipid is critical for optimal formulations. This guide helps navigate the wide range of ionizable lipids for specific therapeutic needs. Explore lipids by target or cargo type.

How to Choose the Right CDMO for Your Pharmaceutical Project

How to Choose the Right CDMO for Your Pharmaceutical Project

This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.

  FEATURED EDITORIAL

  COMPANY PROFILE

upm crdmo

UPM Pharmaceuticals is a contract development and manufacturing organization (CDMO) with 30+ years of US based experience in development to later-stage clinical and commercial manufacturing of oral solid and semi-solid dosage forms.

Beyond our expertise and technology, UPM is a contract manufacturing organization that has a passion for propelling our customers’ journeys from early-stage development to the market, even when the journey doesn’t begin with us. As a large-scale CDMO, technology transfer and scale-up are our specialties; we welcome the opportunity to sit down with you to create a pharma solution by understanding the evolution of your project, your clinical and commercial goals, and how we can work together to get your product across the finish line.

Click here for more.

  WHITEPAPERS & WEBINARS

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

Our client, a leading pharmaceutical company, came to us for a solution to a very specific problem. They needed a staked needle prefilled syringe (PFS) in a disposable auto-injector for their high-concentration monoclonal antibody product. These products are among the …

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability are key.

Gattefossé focuses on customers, veterinarians, pet owners, and animals themselves to help them …

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 16 – ODT/Fast Dissolve
July 23 – Transdermal/Topical Delivery